BPG is committed to discovery and dissemination of knowledge
Minireviews
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Jun 9, 2016; 5(2): 51-58
Published online Jun 9, 2016. doi: 10.5497/wjp.v5.i2.51
Long-term potentiation in autonomic ganglia: Potential role in cardiovascular disorders
Karim A Alkadhi
Karim A Alkadhi, Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, United States
Author contributions: Alkadhi KA contributed all to this paper.
Conflict-of-interest statement: Alkadhi KA declares no conflict of interest related to this publication.
Correspondence to: Karim A Alkadhi, PhD, Professor, Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, SR-2, Cullen Blvd, Houston, TX 77204, United States. kalkadhi@uh.edu
Telephone: +1-713-7431212 Fax: +1-713-7431229
Received: April 22, 2016
Peer-review started: April 28, 2016
First decision: May 13, 2016
Revised: May 21, 2016
Accepted: May 27, 2016
Article in press: June 2, 2016
Published online: June 9, 2016
Processing time: 18 Days and 1.9 Hours
Core Tip

Core tip: Heightened activity of the central nervous system (CNS) caused by epilepsy, chronic stress and CNS stimulants could provide strong preganglionic stimulation of autonomic ganglia, which may trigger expression of ganglionic long-term potentiation (gLTP). Expression of gLTP can result in cardiovascular dysfunction that may lead to morbidity and even mortality.